[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Bhattacharyya NK, De A, Bera P, Sristidhar M, Chakraborty S, Bandopadhyay R: Ovarian tumors in pediatric age group - A clinicopathologic study of 10 years' cases in West Bengal, India. Indian J Med Paediatr Oncol; 2010 Apr;31(2):54-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumors in pediatric age group - A clinicopathologic study of 10 years' cases in West Bengal, India.
  • BACKGROUND AND OBJECTIVES: Objective in this retrospective study is to find out the incidence of different ovarian tumors of girls up to 20 years of age observed in last ten years in North Bengal Medical College and to correlate clinical and gross findings with histopathologic findings and to compare the incidence with other studies and follow-up of patients with malignant ovarian tumors.
  • RESULTS: Total 151 cases of ovarian tumors were received in pathology department in which 34 cases were malignant (22.6%).
  • Amongst malignant cases, 66% are of germ-cell origin-dysgerminoma being the commonest.
  • Strikingly we got 9 cases of malignant surface epithelial tumor.
  • As per follow-up records most of the dysgerminoma came in stage IA and recovered fully following chemotherapy and radiotherapy.
  • CONCLUSIONS: Patients from hilly areas of North Bengal and low socio-economic status led to lower detection rate of ovarian tumors in early stage which are absolutely necessary for proper guidelines of management to reduce mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Obstet Gynecol. 2006;33(3):181-2 [17089585.001]
  • [Cites] Clin Obstet Gynecol. 1977 Sep;20(3):607-23 [196802.001]
  • [Cites] Am J Surg. 1984 Mar;147(3):339-44 [6703205.001]
  • [Cites] Indian J Cancer. 1973 Sep;10(3):302-11 [4362177.001]
  • [Cites] Cancer. 1972 Sep;30(3):713-9 [4342408.001]
  • (PMID = 21209765.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970935
  • [Keywords] NOTNLM ; Germ cell-tumor / Pediatric age group / ovarian tumor / surface epithelial
  •  go-up   go-down


2. Distelmaier F, Calaminus G, Harms D, Sträter R, Kordes U, Fleischhack G, Göbel U, Schneider DT: Ovarian small cell carcinoma of the hypercalcemic type in children and adolescents: a prognostically unfavorable but curable disease. Cancer; 2006 Nov 1;107(9):2298-306
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian small cell carcinoma of the hypercalcemic type in children and adolescents: a prognostically unfavorable but curable disease.
  • BACKGROUND: Ovarian small cell carcinoma of the hypercalcemic type is a rare neoplasm that is associated with a poor prognosis.
  • The objective of the current study was to investigate the clinicopathologic features of this tumor and to develop preliminary diagnostic and therapeutic guidelines.
  • METHODS: Between 1994 and 2005, 11 girls (ages 9-22 years) who were registered on the German Maligne Keimzelltumoren studies and the Kiel Pediatric Tumor Registry were analyzed.
  • Prior to histopathologic review, 8 patients had been misdiagnosed with either germ cell tumor or juvenile granulosa cell tumor.
  • After resection, 4 patients were followed without additional therapy, and all 4 patients developed recurrent disease after 3 to 11 months.
  • Seven patients received adjuvant chemotherapy during first-line treatment.
  • During first-line treatment, high-dose chemotherapy was received by 4 patients who achieved a complete response (CR) after conventional chemotherapy.
  • All 4 of those patients remained in CR for 7 to 73 months, whereas the other 3 patients developed recurrent disease.
  • Salvage treatment after recurrence or tumor progression consisted of surgery and chemotherapy.
  • One patient received high-dose chemotherapy in 2nd CR and remained in 2nd CR.
  • CONCLUSIONS: Patients with ovarian small cell carcinoma of the hypercalcemic type require multiagent chemotherapy during first-line treatment.
  • High-dose chemotherapy may be used to consolidate the therapeutic success.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Hypercalcemia / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16998935.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Biswajit D, Patil CN, Sagar TG: Clinical presentation and outcome of pediatric ovarian germ cell tumor: a study of 40 patients. J Pediatr Hematol Oncol; 2010 Mar;32(2):e54-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation and outcome of pediatric ovarian germ cell tumor: a study of 40 patients.
  • BACKGROUND: Germ cell tumor is a rare malignancy accounting for 3% of all pediatric tumors.
  • The common histologies being mixed germ cell tumor (32%) and dysgerminoma (27%).
  • Ten percent of patients presented with ovarian torsion.
  • CONCLUSIONS: This study confirms an excellent outcome for girls with ovarian germ cell tumor, although majority of the patients presented in advanced stage.
  • Patients with initial histology of Teratoma and Mixed germ cell tumor relapsed frequently.
  • The mainstay of treatment being fertility preservation and cisplatin-based chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Female. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168245.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP, Pediatric Oncology Group 9049, Children's Cancer Group 8882: Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol; 2004 Jul 1;22(13):2691-700
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
  • PURPOSE: To determine in a randomized comparison whether combination chemotherapy with high-dose cisplatin (HDPEB) improves the event-free (EFS) and overall (OS) survival of children and adolescents with high-risk malignant germ cell tumors (MGCT) as compared with standard-dose cisplatin (PEB) and to compare the regimens' toxicity.
  • PATIENTS AND METHODS: Between March 1990 and February 1996, 299 eligible patients with stage III and IV gonadal and extragonadal (all stages) MGCT were enrolled onto this Pediatric Oncology Group and Children's Cancer Group study.
  • Chemotherapy included bleomycin 15 units/m(2) on day 1, etoposide 100 mg/m(2) on days 1 through 5, and either high-dose cisplatin 40 mg/m(2) on days 1 through 5 (HDPEB; n = 149) or standard-dose cisplatin 20 mg/m(2) on days 1 through 5 (PEB; n = 150).
  • Patients were evaluated after four cycles of therapy, and those with residual disease underwent surgery.
  • RESULTS: One hundred thirty-four eligible patients with advanced testicular (n = 60) or ovarian (n = 74) tumors and 165 with stage I to IV extragonadal tumors were enrolled.
  • HDPEB treatment resulted in significantly improved 6-year EFS rate +/- SE (89.6% +/- 3.6% v 80.5% +/- 4.8% for PEB; P =.0284).
  • Tumor-related deaths were more common after PEB (14 deaths v two deaths).
  • Other treatment-related toxicities were more common with HDPEB.
  • CONCLUSION: Combination chemotherapy with HDPEB significantly improves EFS for children with high-risk MGCT.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Etoposide. Female. Humans. Male. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15226336.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13539; United States / NCI NIH HHS / CA / CA30969; United States / NCI NIH HHS / CA / U10CA29139
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


5. Szavay PO, Wermes C, Fuchs J, Schrappe M, Flemming P, von Schweinitz D: Effective treatment of infantile choriocarcinoma in the liver with chemotherapy and surgical resection: a case report. J Pediatr Surg; 2000 Jul;35(7):1134-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of infantile choriocarcinoma in the liver with chemotherapy and surgical resection: a case report.
  • To the authors' knowledge, this is the first report on successful treatment with preoperative chemotherapy.
  • A 10-week-old girl presented with a large liver tumor, ovarian cysts, cardiac insufficiency, progressive hemolytic anemia, and thrombocytopenia.
  • Ultrasound scan and magnetic resonance tomography (MRT) showed the typical pattern of infantile hemangioendothelioma.
  • An emergency laparotomy was performed because of increasing cardiac insufficiency with ligation of the right hepatic artery, tumor biopsy, and subtotal resection of the ovarian cysts.
  • Chemotherapy was initiated with etoposide and cisplatin.
  • When x-ray examination showed development of lung metastases, chemotherapy was intensified with etoposide, cisplatin, and ifosfamid according to the German Study Group of Extracranial Nontesticular Malignant Germ Cell Tumors in Childhood and Adolescence (MAKEI-96).
  • Serum beta-HCG levels decreased further, ultrasound examination showed significant tumor reduction, and pulmonal metastasis could no longer be found in chest x-rays.
  • After the fourth course, a complete tumor resection was achieved by an extended right hemihepatectomy with adjuvant chemotherapy being administered after the operation.
  • The authors' experience shows that chemotherapy is effective for preoperative tumor reduction.
  • [MeSH-major] Choriocarcinoma / drug therapy. Choriocarcinoma / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Infant, Newborn. Remission Induction

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10917316.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


6. Schneider DT, Calaminus G, Wessalowski R, Pathmanathan R, Harms D, Göbel U: Therapy of advanced ovarian juvenile granulosa cell tumors. Klin Padiatr; 2002 Jul-Aug;214(4):173-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of advanced ovarian juvenile granulosa cell tumors.
  • BACKGROUND: Gonadal sex cord-stromal tumors are rare tumors that develop from the gonadal non-germ cell component such as granulosa, Sertoli or Leydig cells.
  • Among these, juvenile granulosa cell tumors (JGCT) constitute the largest subgroup of ovarian sex cord-stromal tumors during childhood and adolescence.
  • In local disease (FIGO stage I), the beneficial role of tumor-ovarectomy is well established.
  • In contrast, life expectancy in patients with advanced JGCT (FIGO stage >/= II) is short even after complete tumor resection.
  • The current literature provides only limited and inconclusive data regarding the value of adjuvant chemotherapy in such patients with advanced disease.
  • PATIENTS AND METHODS: Therefore, we analyzed the patients with FIGO stage >/= II JGCT who were prospectively documented as follow-up patients of the German MAKEI trials for non-testicular germ cell tumors and received the recommended cisplatin-based chemotherapy in an adjuvant setting.
  • Two patients received laparoscopic tumor resection, which was incomplete in both.
  • All patients received 4 or 6 cycles of adjuvant cisplatin-based three-agent chemotherapy in analogy to the current therapeutic concept applied in malignant germ cell tumors.
  • One patient with a large tumor and multiple peritoneal metastases additionally received 40 Gy abdominal irradiation.
  • RESULTS: All patients achieved complete clinical remission after initial surgery and adjuvant chemotherapy.
  • One patient developed a metachronous tumor of the contralateral ovary after 126 months follow-up and is still alive but currently in therapy of another recurrence.
  • Another patient suffered a tumor recurrence after 12 months but achieved a second complete remission with cisplatin chemotherapy after a follow-up of currently 4 months.
  • One patient achieved complete clinical remission but suffered a diffuse peritoneal tumor recurrence with massive ascites and finally died as a result of tumor progression.
  • In summary, at the time of this report 6 of 7 patients are alive after a median of 47 (15 - 138) months.
  • CONCLUSION: This analysis clearly demonstrates that advanced JGCT can be successfully treated with surgery followed by adjuvant cisplatin-based chemotherapy.
  • Therefore, this study reveals encouraging therapeutic perspectives in these otherwise fatal tumors that merit further investigation in a prospective cooperative trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulosa Cell Tumor / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Female. Follow-Up Studies. Germany. Humans. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165898.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer; 2006 Apr;46(4):459-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children: a clinical study of 66 patients.
  • BACKGROUND: Ovarian germ cell tumors are rare in childhood.
  • The aim of this study is to review clinical presentation, management, and outcome in a two-center series of girls with ovarian germ cell tumor.
  • PROCEDURE: The records of 66 patients (median age 9 years) with histologically proven ovarian germ cell tumor (either benign or malignant), treated over a 44-year-span, were reviewed.
  • Sixteen patients had an emergency operation for tumor torsion.
  • Unilateral salpingo-oophorectomy was the most frequently performed procedure (n = 46), and ovarian-sparing tumorectomy was performed in 9 patients (one bilaterally).
  • Surgical removal of the tumor with or without the ovary and/or adnex was the sole treatment in 55 patients, chemotherapy was administered in 10 and radiotherapy + chemotherapy in one.
  • The 64 survivors are now between 8 months and 44 years after treatment.
  • CONCLUSIONS: With a recurrence rate of 4.5% and a mortality rate of 3%, this series confirms the excellent prognosis for girls with ovarian germ cell tumor (GCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206211.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


8. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, Davis M, Giller R, Lauer S, Olson T, Children's Oncology Group (COG): Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg; 2004 Mar;39(3):424-9; discussion 424-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.
  • PURPOSE: The aim of this study was to perform an evaluation of outcome and the role of surgical staging components in malignant germ cell tumors (GCT) of the ovary in children and adolescents.
  • METHODS: From 1990 to 1996, 2 intergroup trials for malignant GCT were undertaken by Pediatric Oncology Group (POG) and Children's Cancer Study Group (CCG).
  • Stage I-II patients were treated with surgical resection and 4 cycles of standard dose cisplatin (100 mg/m2/cycle), etoposide, and bleomycin (PEB) chemotherapy.
  • Stage III-IV patients were treated with surgical resection and randomly assigned to chemotherapy with PEB or high-dose cisplatin (200 mg/m2/cycle) with etoposide and bleomycin (HDPEB).
  • Patients unresectable at diagnosis had second-look operation after 4 cycles of chemotherapy if residual tumor was seen on imaging studies.
  • An analysis of outcome data, operative notes, and pathology reports in girls with ovarian primary site was done for this report.
  • RESULTS: There were 131 patients with ovarian primary tumors of 515 entered on these studies.
  • More aggressive procedure than recommended by guidelines included total hysterectomy and bilateral salpingo-oophorectomy in 6 patients and retroperitoneal node dissection in 10 patients.
  • CONCLUSIONS: Pediatric ovarian malignant GCT (stages I-IV) have excellent survival with conservative surgical resection and platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Infant. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017564.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


9. Lopes LF, Sonaglio V, Ribeiro KC, Schneider DT, de Camargo B: Improvement in the outcome of children with germ cell tumors. Pediatr Blood Cancer; 2008 Feb;50(2):250-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in the outcome of children with germ cell tumors.
  • PURPOSE: To describe the clinical characteristics and estimate the survival of children and adolescents with germ cell tumors treated with cisplatin-based combination chemotherapy according to three different protocols in Brazil.
  • METHODS: From 1983 to 1997, 106 patients were treated at the Hospital do Cancer, Sao Paulo for a diagnosis of germ cell tumor.
  • RESULTS: Patients were treated with only surgery (n = 32), surgery and radiotherapy (n = 1) and chemotherapy (n = 73).
  • From 1983 to 1986 (period I), there were 30 patients and 21 received chemotherapy according to the modified VAB-6 protocol.
  • Twenty-two of 35 patients registered between 1987 and 1991 (period II) were treated with EPO/VAC combination chemotherapy.
  • From 1991 to 1997 (period III), there were 41 patients and 31 received chemotherapy according to the Brazilian TCG-91 protocol.
  • Important prognostic factors included stage (P < 0.001), metastatic status (P < 0.001) and surgical procedure at diagnosis (P < 0.001).
  • An incremental improvement in outcomes was noted across the periods of treatment (P = 0.070).
  • Five-year OS was respectively 42.9 +/- 10.8%, 53.9 +/- 11.4% and 80.6 +/- 7.1% for periods I, II, and III for the patients who received chemotherapy.
  • CONCLUSION: An improvement in the survival of children with germ cell tumors was achieved in the most recent trial (TCG-91) with a risk adapted approach incorporating only cisplatin and etoposide.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / therapy. Ovarian Neoplasms / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17554793.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Palenzuela G, Martin E, Meunier A, Beuzeboc P, Laurence V, Orbach D, Frappaz D: Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg; 2008 Nov;248(5):836-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary.
  • BACKGROUND: The management of malignant germ cell tumors of the ovary (OMGCT) requires multidisciplinary expertise.
  • Relapses occurred in 8 of 24 stage I tumors that were observed (0/8 stage Ia; 5/13 stage Ix (P = 0.044) and 3/3 stage Ic) versus 0/14 stage I treated by adjuvant chemotherapy (P = 0.0015).
  • The risk of relapse was significantly increased if patients underwent postsurgical observation ((HR) = 4.5 (95% CI, 1.5 to 13.3)), and when the tumor contained yolk sac tumor (HR = 7.3 (95% CI, 2.3 to 22.7)).
  • There was no significant prognostic value for age, stage, level of tumor markers at diagnosis, type of surgery, and type of chemotherapy.
  • Patients with stages Ix and Ic tumors may benefit from adjuvant chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Dysgerminoma / diagnosis. Dysgerminoma / surgery. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Fallopian Tubes / surgery. Female. Humans. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Retrospective Studies. Teratoma / diagnosis. Teratoma / pathology. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948812.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


11. Lo Curto M, Lumia F, Alaggio R, Cecchetto G, Almasio P, Indolfi P, Siracusa F, Bagnulo S, De Bernardi B, De Laurentis T, Di Cataldo A, Tamaro P: Malignant germ cell tumors in childhood: results of the first Italian cooperative study "TCG 91". Med Pediatr Oncol; 2003 Nov;41(5):417-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors in childhood: results of the first Italian cooperative study "TCG 91".
  • BACKGROUND AND AIMS: About 20% of patients with germ cell tumor (GCT) are still resistant to therapy.
  • The site of the primary tumor was gonadal in 59, extragonadal in 36.
  • The treatment was surgery alone in 31; surgery plus radiotherapy in 1; chemotherapy +/- surgery in 63.
  • Post-chemotherapy resection in 19 (10 complete, 9 partial).
  • The chemotherapy regimen was carboplatin 400 mg/m2/day on days 1, 2; etoposide 150 mg/m2/day on days 1, 2; ifosfamide 1,500 mg/m2/day on days 21, 22; dactinomycin 1.5 mg/m2/day on day 21; vincristine 1.5 mg/m2/day on day 21.
  • Three patients died because of toxicity and two non-responders (to primary chemotherapy), died of progression; among the remaining 90 patients 20 relapsed, 9 are in second remission, 2 are alive with disease, and 9 died of disease progression (one from progression and intracranial hemorrhage).
  • All the pts who had complete resection of the primary tumor at diagnosis or at delayed surgery, remained in remission.
  • CONCLUSIONS: Multivariate analysis showed that the primary site of tumor was the only independent prognostic factor for survival and EFS.
  • [MeSH-major] Germinoma / pathology. Germinoma / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Confidence Intervals. Female. Humans. Incidence. Italy / epidemiology. Male. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14515380.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Suita S, Shono K, Tajiri T, Takamatsu T, Mizote H, Nagasaki A, Inomata Y, Hara T, Okamura J, Miyazaki S, Kawakami K, Eguchi H, Tsuneyoshi M, Committee for Pediatric Solid Malignant Tumors in the Kyushu Area: Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg; 2002 Dec;37(12):1703-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
  • PURPOSE: This study aims to assess the prognostic factors and optimal treatments for malignant germ cell tumors (MGCT) in childhood.
  • The prognostic factors and treatments were assessed based on the 5-year survival rate. RESULTS:.
  • (1) Stage: 100% for stage I (n = 54), 75.0% for stage II (n = 4), 67.3% for stage III (n = 14), and 54.8% for stage IV (n = 33); Unknown: n = 12. (2) Primary site: 93.4% for the testis (n = 52), 86.7% for the ovary (n = 31), 56.9% for the sacrococcygeal (n = 21), and 60.6% for others (n = 12); unknown: n = 1. (3) Surgical intervention for primary tumor: 100% for stage I with a complete resection (n = 53), 78.4% for stage III, IV with a complete resection (n = 26), and 33.3% for stage III, IV with an incomplete resection (n = 21). (4) Type of chemotherapy for the stage III and IV: 83.9% for the PVB (cisplatin, vinblastin, bleomycin; n = 13), 66.7% for the VAC (vincristine, actinomycin D, cyclophosphamide; n = 6), and 47.1% for other regimens (n = 25).
  • Radical complete resection alone is a sufficient treatment for localized MGCT.
  • The PVB regimen is optimal chemotherapy for advanced MGCT; however, high-risk cases still may require more aggressive treatment.
  • [MeSH-major] Germinoma / diagnosis. Germinoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / surgery. Prognosis. Retrospective Studies. Survival Rate. Testicular Neoplasms / diagnosis. Testicular Neoplasms / epidemiology. Testicular Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • [CommentIn] J Urol. 2003 Sep;170(3):1040 [12926414.001]
  • (PMID = 12483635.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Islam S, Yamout SZ, Gosche JR: Management and outcomes of ovarian masses in children and adolescents. Am Surg; 2008 Nov;74(11):1062-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and outcomes of ovarian masses in children and adolescents.
  • Ovarian masses in the pediatric age group are rare, and malignancies are even less common.
  • We retrospectively reviewed the cases of ovarian masses in children in our institution over a 10-year period.
  • Demographic and tumor-specific data were reviewed and analyzed, and a Student's unpaired t test was used where appropriate.
  • A total of 49 children and adolescents with ovarian masses were found.
  • Eight masses were malignant (16%) with malignant teratoma, dysgerminoma, and germ cell tumors found.
  • These patients responded to chemotherapy, but there were three recurrences noted that responded to further therapy.
  • A majority of the patients underwent a laparotomy with 12 per cent having a minimally invasive procedure.
  • Only 37 per cent of the operations were performed by the pediatric surgeons.
  • Most ovarian masses in childhood are benign.
  • Malignant lesions have favorable outcomes with chemotherapy, even with recurrent disease.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Incidence. Laparoscopy. Laparotomy. Ovariectomy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062661.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Murphy JJ, Tawfeeq M, Chang B, Nadel H: Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J Pediatr Surg; 2008 Dec;43(12):2186-92
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms.
  • PURPOSE: Positron emission tomography/computerized tomography (PET/CT) scan provides both functional and anatomical information in a single diagnostic test.
  • It has the potential to be a valuable tool in the evaluation of pediatric abdominal tumors.
  • These included Burkitt's lymphoma (8), neuroblastoma (7), rhabdomyosarcoma (6), ovarian tumor (3), Wilms' tumor (2), hepatocellular carcinoma (2), paraganglioma (1), germ cell tumor (1), undifferentiated sarcoma (1), renal primitive neuroectodermal tumor (1), gastrointestinal stromal tumor (1), adrenocortical carcinoma (1), inflammatory pseudotumor (1), and adrenal adenoma (1).
  • These include (1) preoperative staging, (2) selection of appropriate site for biopsy, (3) identification of occult metastatic disease, (4) follow-up for residual or recurrent disease, and (5) assessment of response to chemotherapy.
  • CONCLUSIONS: Preliminary data indicate that PET/CT is a promising tool in the evaluation of pediatric abdominal malignancies.
  • [MeSH-major] Abdominal Neoplasms / radiography. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Drug Monitoring. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Male. Neoplasm Staging / methods. Neoplasm, Residual. Postoperative Care / methods. Preoperative Care / methods. Radiopharmaceuticals / pharmacokinetics. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040932.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


15. Aygun B, Kimpo M, Lee T, Valderrama E, Leonidas J, Karayalcin G: An adolescent with ovarian osteosarcoma arising in a cystic teratoma. J Pediatr Hematol Oncol; 2003 May;25(5):410-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An adolescent with ovarian osteosarcoma arising in a cystic teratoma.
  • A 14-year-old girl had an abdominal mass with the characteristics of an ovarian germ cell tumor on computed tomography scan.
  • Seven months after completion of chemotherapy, there were simultaneous local recurrence and lung metastases.
  • Previously, 10 cases of ovarian osteosarcoma have been reported in the literature: 5 were primary osteosarcoma of the ovary, 4 were associated with teratomas, and 1 was part of a malignant mixed mesodermal tumor of the ovary.
  • Of the 10, there are only 2 long-term survivors, both of whom were treated with adjuvant chemotherapy following complete resection.
  • [MeSH-major] Osteosarcoma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12759630.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


16. Schneider DT, Calaminus G, Harms D, Göbel U, German Maligne Keimzelltumoren Study Group: Ovarian sex cord-stromal tumors in children and adolescents. J Reprod Med; 2005 Jun;50(6):439-46
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian sex cord-stromal tumors in children and adolescents.
  • Ovarian sex cord-stromal tumors (OSCSTs) are a heterogeneous group of tumors that develop from the gonadal non-germ-cell component.
  • Despite recent advances in the clinical and histopathologic diagnosis of OSCSTs, a high degree of uncertainty remains with regard to adequate therapy, particularly in patients presenting with microscopic or macroscopic tumor spread.
  • In addition, we summarize the data from our clinical, histopathologic and genetic analyses of patients that were prospectively reported to the German MAKEI protocols for treatment of nontesticular malignant germ cell tumors.
  • Among these patients, juvenile granulosa cell tumors (JGCTs) constitute the most frequent histologic subtype, followed by Sertoli-Leydig cell tumors (SLCTs) and sclerosing stromal tumors.
  • Patients with JGCT and SLCT show greater mitotic activity than do all those with other histologic types.
  • In addition, prognosis correlates with tumor stage according to the International Federation of Obstetrics and Gynecology.
  • Nevertheless, we observed a favorable response to cisplatin-based chemotherapy in the majority of stage II and III tumors.
  • This analysis confirmed that most OSCSTs present at a low tumor stage and that prognosis in these patients is excellent.
  • Most important, patients at high risk can be identified through clinical and histopathologic analysis, and the majority can be treated successfully with adjuvant cisplatinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / therapy. Sex Cord-Gonadal Stromal Tumors / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Germany. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050568.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 27
  •  go-up   go-down


17. Biskup W, Calaminus G, Schneider DT, Leuschner I, Göbel U: Teratoma with malignant transformation: experiences of the cooperative GPOH protocols MAKEI 83/86/89/96. Klin Padiatr; 2006 Nov-Dec;218(6):303-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The designation of a teratoma with malignant transformation (TMT) refers to the occurrence of somatic non-germ cell malignancies within a teratoma.
  • While TMT is a rare but well recognised phenomenon in adult germ cell tumors (GCT), data on TMT in pediatric GCTs are lacking.
  • PATIENTS AND METHODS: Between 1982 and 2003, 641 patients with extracranial nontesticular pure teratoma (256 coccygeal, 246 ovarian, 139 other sites) were reported to the MAKEI protocols 83/86/89/96 by various, mainly German centres.
  • Patients with malignant germ cell tumor components were excluded from this analysis.
  • Two patients had coccygeal teratomas and seven ovarian tumors.
  • Resection was performed in seven patients (including both coccygeal tumors) and adjuvant chemotherapy was administered in one of them.
  • Two patients relapsed after resection, but both were cured with chemotherapy.
  • Two patients suffered from advanced tumors and both were treated with primary chemotherapy.
  • CONCLUSIONS: Malignant transformation of pure teratomas constitutes a very rare entity in children and adolescents that is most commonly observed in postpubertal girls with ovarian teratoma.
  • In localised tumors, complete resection appears to be adequate, whereas chemotherapy should be considered in patients with R1- or R2-resection.
  • Cisplatinum-based chemotherapy was effective as two of four relapsed patients survived tumor free.
  • However, the ideal regimen has not yet been established and the known sensitivity of the histologic components to cytostatic drugs has to be considered in the choice of treatment.
  • [MeSH-major] Ovarian Neoplasms. Teratoma
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Child. Child, Preschool. Cytogenetic Analysis. Female. Humans. Infant. Infant, Newborn. Middle Aged. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / pathology. Ovary / pathology. Sacrococcygeal Region / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080331.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


18. Mutafoğlu-Uysal K, Sarialioğlu F, Olgun N: Bleomycin-induced hyperpigmentation and hypersensitivity reactions to etoposide and vinblastine in a child with endodermal sinus tumor. Turk J Pediatr; 2001 Apr-Jun;43(2):172-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleomycin-induced hyperpigmentation and hypersensitivity reactions to etoposide and vinblastine in a child with endodermal sinus tumor.
  • We report a pediatric case who developed bleomycin-induced hyperpigmentation and hypersensitivity reactions to both etoposide and vinblastine while receiving chemotherapy for germ cell tumor.
  • Skin hyperpigmentation related to chemotherapeutic agents has been reported only rarely in pediatric patients.
  • This patient developed a characteristic skin hyperpigmentation which was "flagellate" in appearance.
  • Two features of the hyperpigmentation were noteworthy: development at a low cumulative dose of bleomycin and persistence after cessation of chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bleomycin / adverse effects. Drug Hypersensitivity / complications. Endodermal Sinus Tumor / complications. Etoposide / immunology. Hyperpigmentation / complications. Ovarian Neoplasms / complications. Vinblastine / immunology

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432501.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


19. Robova H, Rob L, Hrehorcak M, Zoban P, Prusa R: Endodermal sinus tumor diagnosed in pregnancy: a case report. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):914-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endodermal sinus tumor diagnosed in pregnancy: a case report.
  • Pure endodermal sinus tumor (EST) of the ovary is an uncommon germ cell tumor characterized by rapid growth.
  • Further, three cycles of combination chemotherapy (cisplatin, bleomycin, and etoposide) were administered.
  • The child showed normal laboratory, pediatric, and neurologic examination at the time of discharge from hospital and during the first and second years of her life.
  • We conclude that the prognosis of EST is very good if patient receives adjuvant therapy.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Infant, Newborn. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17635618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Razzi S, Luisi S, Gabbanini M, Lazzeri L, Mazzini M, Petraglia F: Yolk sac tumor in a young girl: a case report. Gynecol Endocrinol; 2005 Jun;20(6):334-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yolk sac tumor in a young girl: a case report.
  • BACKGROUND: Yolk sac tumor is a rare neoplasm characterized by high malignancy given its premature metastasis, that is frequent in adolescence.
  • CASE REPORT: A 21-year-old woman came to our observation for an ovarian cyst (13 cm in diameter).
  • Following salpingo-oophorectomy, it was revealed as a yolk sac tumor by histological diagnosis.
  • She is now undergoing chemotherapy treatment.
  • CONCLUSION: This is an interesting case of yolk sac tumor in a young girl, at an age typical for germ cell tumor.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents. Combined Modality Therapy. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Humans. Ovariectomy

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019383.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Göbel U, Calaminus G, Schneider DT, Koch S, Teske C, Harms D: The malignant potential of teratomas in infancy and childhood: the MAKEI experiences in non-testicular teratoma and implications for a new protocol. Klin Padiatr; 2006 Nov-Dec;218(6):309-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The malignant potential of teratomas in infancy and childhood: the MAKEI experiences in non-testicular teratoma and implications for a new protocol.
  • Since 1982, mature and immature teratomas have been recruited into the MAHO and MAKEI protocols of the German Society for Pediatric Oncology and Hematology (GPOH) for testicular and non-testicular germ cell tumors in order to study the epidemiology and clinical behaviour of teratomas.
  • Patients were registered in the epidemiologic German Childrens Cancer Registry and the GPOH Childrens Tumor Registry for pathological review.
  • Patients with immaturity grade 2 and 3 according to Gonzales-Crussi were eligible for adjuvant chemotherapy.
  • 1) EFS after complete tumor resection has been estimated to 0.96 +/- 0.01 in both observation periods.
  • 2) Incomplete tumor resection remains the main risk factor for relapse (EFS 0.55 +/- 0.09).
  • 4) In MAKEI 83/86/89 four newborns with teratoma died due to perioperative complications and nine children as a result of tumor progression, whereas in MAKEI 96 no newborn died, only one child died from tumor progression, and another child died during long time observation for another reason (meningitis).
  • 5) In accordance to the experience of the MAKEI 83/86/89 studies, no child of the MAKEI 96 study presented with yolk sac tumor at recurrence if adjuvant chemotherapy was administered during first-line treatment because of immaturity.
  • In contrast, more than half of the children with tumor recurrence after watch and wait strategy had yolk sac tumor in addition to teratoma.
  • [MeSH-major] Ovarian Neoplasms. Teratoma
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Data Interpretation, Statistical. Disease Progression. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / pathology. Ovary / pathology. Prospective Studies. Randomized Controlled Trials as Topic. Sacrococcygeal Region. Sex Factors. Treatment Outcome. World Health Organization

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080332.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


22. Nimkin K, Gupta P, McCauley R, Gilchrist BF, Lessin MS: The growing teratoma syndrome. Pediatr Radiol; 2004 Mar;34(3):259-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Growing teratoma syndrome is defined as enlarging masses of mature teratoma following chemotherapy for malignant nonseminomatous germ-cell tumors.
  • Typically, there is associated normalization of initially elevated serum tumor markers.
  • [MeSH-major] Neoplasm Recurrence, Local. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Female. Gynecologic Surgical Procedures / methods. Humans. Neoplasm Metastasis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Int. 1995;55(4):226-8 [8588272.001]
  • [Cites] Clin Radiol. 1991 Jun;43(6):402-8 [2070582.001]
  • [Cites] Ann Med. 2002;34(5):316-23 [12452476.001]
  • [Cites] J Obstet Gynaecol Res. 2002 Jun;28(3):166-71 [12214834.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1629-35 [6288220.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):942-7 [9307195.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):385-90 [1473754.001]
  • [Cites] Ann Thorac Surg. 1997 Aug;64(2):359-62 [9262575.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1389-94 [10899652.001]
  • (PMID = 14551755.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Hummel T, Hord JD: Favorable response to soft tissue sarcoma therapy in an adolescent with embryonal renal sarcoma. Pediatr Blood Cancer; 2004 Jul;43(1):70-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable response to soft tissue sarcoma therapy in an adolescent with embryonal renal sarcoma.
  • Embryonal renal sarcomas were first identified in 1995 among banked tumor samples originally classified as adult Wilms tumor.
  • Few long-term remissions were observed when these rare tumors were treated with chemotherapy usually used for childhood Wilms.
  • Data were collected from the medical record of an adolescent female with embryonal renal sarcoma and treated with sarcoma-directed chemotherapy and radiation.
  • At 66 months following diagnosis, the patient has no evidence of tumor but has experienced severe renal dysfunction and ovarian failure.
  • We believe there is a subset of patients with disseminated embryonal renal sarcoma that respond to intense sarcoma-directed therapy.
  • [MeSH-major] Kidney Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans






Advertisement